M. Coşkun
{"title":"Central serous chorioretinopathy developed following covid-19 vaccine","authors":"M. Coşkun","doi":"10.37845/ret.vit.2023.32.12","DOIUrl":null,"url":null,"abstract":"A 40-year-old male patient, an office worker, is a hospital staff. He applied with the complaint of sudden onset of blurred vision in the right eye. He stated that he had the first dose of inactivated covid vaccine (sinovac) 4 days ago in his story. In his examination, his vision was 0.5 in the right eye, 1.0 in the left eye, and his intraocular pressure was in both eyes. It was at the level of 15 mmHg. Biomicroscopically, the anterior segment looked natural. CSC was diagnosed in the FFA and OCT examinations.Treatment with oral acetazolamide (2x250 mg), topical nepafanac (4x1) was started. On the 13th day of the treatment, there was insufficient improvement in clinical findings, and oral acetazolamide was used. The dose was reduced (2x125 mg), oral epleronone (50 mg) was added. On the 70th day of the treatment, the vision in the right eye increased to full level in the control examination and it was observed that the retina returned to its normal appearance in the OCT examination.Copyright © 2023 Gazi Eye Foundation. All rights reserved.","PeriodicalId":17086,"journal":{"name":"Journal of Retina-Vitreous","volume":"53 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Retina-Vitreous","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37845/ret.vit.2023.32.12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
covid-19疫苗接种后出现中枢性浆液性脉络膜视网膜病变
患者男,40岁,办公室职员,是医院职员。他以右眼突然视力模糊为主诉来申请的。他在4天前的故事中说,他接种了第一剂灭活疫苗(sinovac)。检查右眼视力0.5,左眼视力1.0,双眼眼压均为正常。在15毫米汞柱的水平。生物显微镜下,前段看起来很自然。经FFA和OCT检查诊断为CSC。开始口服acetazolamide (2x250 mg),外用neafanac (4x1)。治疗第13天,临床表现改善不足,改用口服乙酰唑胺。减少剂量(2 × 125 mg),加入口服依普利酮(50 mg)。治疗第70天,对照检查右眼视力恢复正常,OCT检查视网膜恢复正常。版权所有©2023加兹眼科基金会。版权所有。
本文章由计算机程序翻译,如有差异,请以英文原文为准。